• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Methylpentynol     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatTertiaryAlcoholsyago:Abstraction100002137yago:Acetylene114600742yago:Agent114778436yago:Alcohol107884567yago:AliphaticCompound114601294yago:Beverage107881800yago:CausalAgent100007347yago:Chemical114806838yago:Compound114818238yago:Drug103247620yago:DrugOfAbuse103248958yago:Fluid114939900yago:Food100021265yago:Liquid114940386yago:Material114580897yago:Matter100020827yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:Relation100031921drugyago:Substance100019613yago:Substance100020090yago:WikicatAlcoholsyago:WikicatAlkynesumbel-rc:DrugProduct New Facet based on Instances of this Class

Methylpentynol (Methylparafynol, Dormison, Atemorin, Oblivon) is a tertiary hexynol with hypnotic/sedative and anticonvulsant effects and an exceptionally low therapeutic index. It was discovered by Bayer in 1913 and was used shortly thereafter for the treatment of insomnia, but its use was quickly phased out in response to newer drugs with far more favorable safety profiles.